Low Dose Naltrexone For Inflammatory Hair Loss 3/16/2025
Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Research and Question about Allopregnanolone, Multiple Sclerosis, TRT, and Finasteride
A 52-year-old male with Multiple Sclerosis is considering using Finasteride and Testosterone Replacement Therapy (TRT) for hair loss but is advised to lose weight first to avoid side effects. He is currently focusing on diet, weight loss, and using Rogaine and microneedling for hair treatment.
community Additional supplements / peptides to maximize finasteride benefit
The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.
community 8 years of hair loss, turning 30 next month
The user has been dealing with hair loss for 10 years, worsened by psoriasis, and uses minoxidil and finasteride. They seek advice on managing psoriasis and hair loss, with suggestions to see a dermatologist, try different shampoos, and be patient.
community The Worst Hair Loss Condition You (MAY) have: LPP
Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.
community Low dose finestaride 6 month progress (0,25mg)
The user shared their 6-month progress using 0.25 mg finasteride, topical minoxidil, and dermastamping, noting good results but experiencing increased sleepiness. Another user suggested minoxidil might be causing the sleepiness, and the original poster considered adjusting their treatment.
Related Research
6 / 6 resultsresearch Reversible Hair Loss in Lichen Planopilaris: Regrowth With Low-Dose Naltrexone and Platelet-Rich Plasma
This case report describes a patient with lichen planopilaris who experienced remarkable hair regrowth at a previously scarred area after treatment with low-dose naltrexone and platelet-rich plasma, following minimal response to other therapies.
research Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study
In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.
research Optimal Management of Frontal Fibrosing Alopecia: A Practical Guide
This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.
research Treatment of frontal fibrosing alopecia: literature review 2020-2025
In this narrative review, researchers evaluated existing literature on the treatment of frontal fibrosing alopecia, finding that while no curative treatment exists, clinical improvements can be achieved through personalized and combined therapy approaches.
research Frontal Fibrosing Alopecia – a review and a practical guide for clinicians
This review provides a detailed analysis of frontal fibrosing alopecia, focusing on its prevalence in postmenopausal Caucasian women, associated comorbidities, and potential autoimmune, genetic, hormonal, and environmental factors; it emphasizes the need for improved understanding to enhance diagnosis and treatment.
research A Review of the Characteristics of Clinical Trials and Potential Medications for Alcohol Dependence: Data Analysis from ClinicalTrials.gov
This study provides a detailed overview of 1,295 clinical trials related to alcohol dependence registered on ClinicalTrials.gov, highlighting that 59.15% of these trials have been completed, primarily as interventional studies, with most located in North America.